Table 2.
Surgical and pathological characteristics of patients who underwent surgery.
| Characteristic | n (%) |
|---|---|
| Total | 16 (100) |
| Time interval to surgery, days, median (range) | |
| From start of CRT to surgery | 97 (69-121) |
| From end of CRT to surgery | 56 (42-80) |
| Surgery | |
| Duration of surgery, minutes, median (range) | 485 (369-802) |
| Neck dissection | |
| Ipsilateral | 16 (100) |
| Contralateral | 16 (100) |
| Number of dissected nodes, ipsilateral, median (range) | 24 (11-60) |
| Number of dissected nodes, contralateral, median (range) | 18 (5-39) |
| Flap plastic | |
| Regional | 5 (31) |
| Vastus lateralis | 4 (25) |
| Vastus lateralis and anterolateral thigh | 2 (13) |
| Deltopectoral | 2 (13) |
| Rectus abdominis | 1 (6) |
| Radial forearm | 1 (6) |
| Fibula | 1 (6) |
| Residual tumor | |
| R0 | 16 (100) |
| R1/2 | 0 (0) |
| Pathologic T category | |
| ypT0 | 8 (50) |
| ypT1 | 4 (25) |
| ypT2 | 0 (0) |
| ypT3 | 0 (0) |
| ypT4 | 4 (25) |
| Pathologic N category | |
| ypN0 | 13 (81) |
| ypN1 | 2 (13) |
| ypN2a | 0 (0) |
| ypN2b | 1 (6) |
| ypN2c | 0 (0) |
| ypN3 | 0 (0) |
| Tumor regression grading# | |
| 1 | 8 (51) |
| 2 | 6 (37) |
| 3 | 1 (6) |
| 4 | 1 (6) |
| Primary tumor regression pattern | |
| Tumor shrinkage | 3 (19) |
| Tumor fragmentation | 5 (31) |
| Pathologic complete response | 8 (59) |
| Postoperative morbidity | |
| Clavien-Dindo classification | |
| None | 5 (31) |
| Grade 1 | 1 (6) |
| Grade 2 | 1 (6) |
| Grade 3a | 4 (25) |
| Grade 3b | 5 (31) |
| Grade 4 | 0 (0) |
| Grade 5 | 0 (0) |
| NCI-CTCAE* complications | |
| None | 5 (31) |
| Grade 1 | 1 (6) |
| Grade 2 | 1 (6) |
| Grade 3 | 9 (56) |
| Grade 4 | 0 (0) |
| Grade 5 | 0 (0) |
| NCI-CTCAE* complications grade ≥3 | |
| Wound complication (including 1 loss of flap) | 3 (19) |
| Oral hemorrhage | 4 (25) |
| Hematoma | 1 (6) |
| Laryngeal edema | 1 (6) |
*National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. #Tumor regression of the primary tumor following neoadjuvant chemoradiotherapy according to Braun et al., 1989. CRT, Chemoradiotherapy.